Abstract

BackgroundRegarding therapeutic adherence to new oral anticoagulants (NOAC), several studies1 have shown lower adherence in dabigatran-treated patients compared to rivaroxaban and apixaban. The NOAC introduction has fueled the phenomenon of...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call